Novo Nordisk (NVO) shares are up 2.30% to $104.99 as of 11:24 am on Friday, rising from its previous close of $102.63 on November 21st. The stock's upward movement is primarily driven by news of a strategic partnership with Swiss medical device manufacturer Ypsomed. This collaboration involves the supply of injection pens for Novo Nordisk's upcoming obesity treatment, CagriSema, which is currently in late-stage clinical development. The new treatment combines semaglutide, the active ingredient in the company's popular weight-loss drug Wegovy, with another compound that mimics the metabolic hormone amylin. Novo Nordisk aims for CagriSema to achieve an average weight loss of 25% within a year, potentially surpassing competitor Eli Lilly's weight-loss treatments. The partnership with Ypsomed is expected to enhance the delivery of Novo Nordisk's innovative therapies, contributing to the positive sentiment around the stock.